Table 2 Accrual summary.

From: A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors

Dose level

Accrual period

No. enrolled pts

No. canceled/replaced pts

No. evaluable pts

DLTs

1

10/6/17–11/22/17

5

2

3

2

1/22/18–4/20/18

4

1

3

3

6/5/18–8/22/18

4

1

3

4

10/4/18–12/21/18

6

0

6

MTD (expansion)

2/4/19–10/15/19

24

4

20

3